Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer
Andrea B. Apolo(National Institutes of Health), Sundeep Agrawal(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Jamie Marko(National Institutes of Health Clinical Center), V. Ellen Maher(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Lauren Kim(National Institutes of Health), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Harpreet Singh(United States Food and Drug Administration), Mohammadhadi Bagheri(National Institutes of Health Clinical Center), Seth P. Lerner(Baylor College of Medicine), Brant A. Inman(Duke Medical Center), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Richard Pazdur(United States Food and Drug Administration), Gary D. Steinberg(Rush University Medical Center), Ryan P. Werntz(University of Chicago), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Venkatesh Krishnasamy(National Institutes of Health), Randy F. Sweis(University of Illinois Chicago), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Ke Liu(Peking University), Rick Bangs(Bladder Cancer Advocacy Network), F Richardson Cross(United States Food and Drug Administration), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 9
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k